Condition 1: Hypertdnsion. Condition 2: Obesity. Condition 3: Hyperlipidemia. Condition 4: NAFLD. Condition 5: Depression. Condition 6: Blood glucose. Condition 7: crp, homocystein. Essential (primary) hypertension Overweight and obesity Hyperlipidemia, unspecified Fatty (change of) liver, not elsewhere classified Major depressive disorder, single episode, mild Abnormal glucose Other specified abnormal findings of blood chemistry
Conditions
Interventions
Intervention 1: Intervention group: At the beginning of the study, the objectives and methodology will be explained to participants, and if they are willing to take part, written consent will be obtai
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Individuals aged 30 to 60 years Regular participation in training, nutritional, psychological, and physical activity sessions
Exclusion criteria
Exclusion criteria: Individuals who are retired or unemployed Individuals who are currently working individuals with disabilities COVID-19 infection, history of heart disease, autoimmune diseases (e.g., lupus), or acute systemic History of mental health disorders: schizophrenia, bipolar disorder, or major depression leading to hospitalization in the last 6 months Professional athletes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination and comparison of baseline variables, various aspects of lifestyle, and the prevalence of chronic diseases (including cardiovascular diseases, metabolic syndrome, diabetes, and fatty liver disease) at the beginning of the study among the study participants. Timepoint: at baseline. Method of measurement: questionnaire and biochemical tests.;Determination and comparison of the main cardiovascular disease risk factors (hs-CRP, homocysteine), liver function tests (AST, ALT, ALP), glycemic status (fasting serum glucose), and serum lipid profile (triglycerides, total cholesterol, HDL-C, calculated LDL-C, LDL-C/HDL-C, TG/HDL-C, TC/HDL-C) before and after the intervention in the intervention and control groups. Timepoint: at baseline and end of the trial. Method of measurement: biochemical tests.;Determination and comparison of systolic and diastolic blood pressure levels before and after the intervention in the intervention and control groups. Timepoint: at baseline and end of the trial. Method of measurement: Digital sphygmomanometer.;Determination and comparison of total energy intake, carbohydrate, total fat, saturated fatty acids, unsaturated fatty acids, MUFA, PUFA, and dietary cholesterol before and after the intervention in the intervention and control groups. Timepoint: at baseline and end of the trial. Method of measurement: food frequency questionnaire.;Determination and comparison of anthropometric indices (weight, body mass index [BMI], waist circumference, muscle mass percentage, and body fat percentage) in employees before and after the intervention in the intervention and control groups. Timepoint: at baseline and end of the trial. Method of measurement: Body composition analyzer device.;Assessment of quality of life scores in the intervention and control groups. Timepoint: at besline. Method of measurement: sf-36 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Amani
Esfahan University of Medical Sciences
Outcome results
None listed